Table. Characteristics of the Matched Patient Groups at Baseline.
| Characteristic | Matched comparison: AHSCT and fingolimod | Matched comparison: AHSCT and natalizumab | Matched comparison: AHSCT and ocrelizumab | ||||||
|---|---|---|---|---|---|---|---|---|---|
| AHSCT | Fingolimod | d | AHSCT | Natalizumab | d | AHSCT | Ocrelizumab | d | |
| Patients matched, No. | 144 | 769 | NA | 146 | 730 | NA | 110 | 343 | NA |
| Male, No. (%) | 44 (30.6) | 224 (29.1) | 0.03 | 45 (30.8) | 224 (30.6) | 0.01 | 36 (32.7) | 120 (35.0) | 0.05 |
| Female, No. (%) | 100 (69.4) | 545 (70.9) | NA | 101 (69.2) | 506 (69.4) | NA | 74 (67.3) | 223 (65.0) | NA |
| Age, mean (SD), y | 35.7 (8.7) | 35.3 (9.4) | 0.04 | 35.5 (8.7) | 36.0 (9.0) | 0.06 | 37.0 (8.6) | 37.1 (10.6) | 0.01 |
| MS duration, mean (SD), y | 8.12 (5.58) | 8.17 (6.07) | 0.01 | 7.92 (5.63) | 8.17 (6.22) | 0.04 | 8.68 (5.42) | 8.48 (7.34) | 0.03 |
| Relapses in prior 12 mo, mean (SD) | 0.80 (0.97) | 0.81 (0.92) | 0.02 | 0.82 (1.01) | 0.86 (0.89) | 0.04 | 0.79 (0.95) | 0.77 (0.94) | 0.03 |
| Relapses in prior 24 mo, mean (SD) | 1.12 (1.27) | 1.17 (1.20) | 0.04 | 1.17 (1.33) | 1.19 (1.14) | 0.02 | 1.15 (1.25) | 1.08 (1.19) | 0.06 |
| Baseline EDSS score, mean (SD) | 3.74 (1.63) | 3.75 (1.82) | 0.00 | 3.86 (1.66) | 3.88 (1.92) | 0.02 | 3.50 (1.60) | 3.58 (1.87) | 0.05 |
| Patients with prebaseline progression, No. (%) | 23 (16.0) | 168 (21.8) | 0.15 | 23 (15.8) | 197 (27.0) | 0.28 | 20 (18.2) | 69 (20.0) | 0.05 |
| Top prebaseline DMT (%) | |||||||||
| Low efficacy | 18 (12.5) | 104 (13.5) | 0.05 | 18 (12.3) | 87 (12.0) | 0.03 | 14 (12.7) | 43 (12.5) | 0.03 |
| Medium efficacy | 9 (6.2) | 46 (5.9) | 12 (8.2) | 55 (7.5) | 10 (9.1) | 30 (8.7) | |||
| High efficacy | 24 (16.7) | 139 (18.2) | 17 (11.6) | 88 (12.1) | 22 (20.0) | 73 (21.3) | |||
| Unknown | 93 (64.6) | 480 (62.4) | 99 (67.8) | 500 (68.5) | 64 (58.2) | 197 (57.5) | |||
| Region, No. (%) | |||||||||
| Asia-Pacific | 46 (31.9) | 236 (30.7) | 0.03 | 46 (31.5) | 230 (31.5) | 0.07 | 45 (40.9) | 148 (43.2) | 0.05 |
| Europe | 73 (50.7) | 392 (51.0) | 73 (50.0) | 346 (47.4) | 50 (45.5) | 148 (43.0) | |||
| North America | 25 (17.4) | 141 (18.3) | 27 (18.5) | 154 (21.1) | 15 (13.6) | 47 (13.8) | |||
| Study follow-up, mean (SD), ya | 4.01 (2.59) | 2.84 (2.43) | 0.46 | 4.08 (2.67) | 2.51 (2.22) | 0.64 | 3.78 (2.43) | 1.52 (0.94) | 1.22 |
| Year of baseline, median (IQR) | 2015 (2013-2017) | 2013 (2012-2015) | 0.17 | 2015 (2013-2016) | 2012 (2010-2015) | 0.44 | 2016 (2014-2017) | 2018 (2018-2019) | 1.40 |
| MRI: T2 lesion, No. (%) | |||||||||
| 0 | 0. (0.0) | 4 (0.5) | 0.76 | 0 (0.0) | 1 (0.1) | 0.84 | 0 (0.0) | 9 (2.5) | 1.04 |
| 1-2 | 3 (2.1) | 27 (3.5) | 3 (2.1) | 35 (4.8) | 3 (2.7) | 9 (2.7) | |||
| 3-8 | 5 (3.5) | 130 (17.0) | 4 (2.7) | 125 (17.2) | 5 (4.5) | 53 (15.6) | |||
| ≥9 | 45 (31.2) | 374 (48.6) | 46 (31.5) | 367 (50.3) | 38 (34.5) | 220 (64.1) | |||
| Unknown | 91 (63.2) | 234 (30.5) | 93 (63.7) | 202 (27.7) | 64 (58.2) | 52 (15.1) | |||
| Visit interval, mean (SD), mo | 8.38 (4.43) | 4.46 (4.02) | 0.93 | 8.39 (4.42) | 3.99 (4.41) | 0.99 | 8.77 (4.70) | 5.48 (3.57) | 0.79 |
Abbreviations: AHSCT, autologous hematopoietic stem cell transplant; DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; MRI, magnetic resonance imaging; MS, multiple sclerosis; NA, not applicable.
a
Study follow-up is shown before pairwise-censoring was applied.